# Phase 6 — Go / No-Go Review

The decision follows the documented evidence (`phase6_objective_acceptance_matrix.md`,
`phase6_integrated_findings.md`, `phase6_reproducibility_audit.md`,
`phase6_security_and_leakage_audit.md`). It is not assumed in advance.

## Decision

## → GO FOR PHASE 7

**Final curator decision. This is not conditional.** All ten Phase 6 objectives passed. The
Phase 7 entry safeguards below are **standing governance requirements**, not unresolved Phase 6
defects.

**Scope of the GO:** Phase 7 is authorized **only** as the **robustness track** described in
`phase7_handoff.md`. The GO does **not** authorize production release, holdout access,
external-validation claims, taxonomy changes, or result-driven case changes.

## Why GO (evidence)

1. **All ten Phase 6 objectives PASS** (two with forward-looking notes that are Phase 7
   design inputs, not defects).
2. **Infrastructure is technically and methodologically functional**: governance levels,
   packet integrity, confidence semantics, a committed development-pool commitment, a runtime
   freeze, a frozen calibration engine, a validated report prototype, and a paired pilot — all
   with separate prep/result checkpoints and hashed contracts.
3. **Reproducibility is clean**: public-fixture generators reproduce byte-for-byte;
   envelope-dependent results are provably unchanged; full suite (1309) + Phase 6 targeted
   (316) + ruff pass.
4. **Leakage posture is clean**: Phase 6 introduced no private identity, mapping, raw
   response, salt, or holdout material into Git; the holdout stayed sealed.
5. **The scientific results justify the next step**: a descriptive Agent-Arena advantage on
   the paired pilot, an informative Brier-over-ECE finding, an unproven abstention rule, and a
   recurring overclaim-boundary difficulty signal — each is precisely what a robustness phase
   is designed to probe.

## Why not NO-GO

No blocking defect exists: no failed objective, no reproducibility break, no leakage, no
methodology drift, no altered result. Nothing prevents a well-scoped next phase.

## Standing Phase 7 entry safeguards (governance requirements, not Phase 6 defects)

These are **standing governance requirements** on how Phase 7 is entered — a continuation of
the Level-2/3 discipline used throughout Phase 6. They do **not** qualify or weaken the GO, and
none reflects an unresolved Phase 6 defect. Phase 7 must satisfy them before any execution:

1. **Freeze a replication count before execution** (consider 3–5 where justified) and define
   deterministic aggregation + disagreement reporting **before** results. Do not reinterpret
   replication frequency as a calibrated correctness probability.
2. **No result-driven case changes**: preserve all existing cases; do not retire easy cases
   because models solved them; nominate harder diagnostic cases **separately**; no relabeling.
3. **Holdout stays sealed** unless a separate, explicit, pre-registered curator decision
   opens it. This closeout does **not** authorize holdout access.
4. **No production or universal-superiority claim** may be made from Phase 7 development
   evidence; Brier remains primary, ECE secondary.
5. **Taxonomy/gold/thresholds/costs remain frozen**; the overclaim-boundary pattern is a
   hypothesis to test, not a defect to "fix".

## Explicitly out of scope for the GO

Robustness *implementation*, external/human validation, product release engineering, and
holdout evaluation are **not** started here and are **not** authorized by this GO beyond
planning (`phase7_handoff.md`).
